Key Highlights

  • Enlivex Therapeutics (NASDAQ:ENLV) is down 20.79%, quoted at USD 1.41, with an RSI of 11.69 and Volume 2.71 times the typical level, per the screen used here. Every figure is unverified.
  • Market data published on November 4, 2026 listed USD 1.43, a Market Capitalisation near USD 2.19 million and 1.53 million shares. The 52-week span of USD 1.40 to USD 434.40 is shaped by reverse splits.
  • The company disclosed a Nasdaq delisting notice on October 27, 2026 and stated it plans to appeal. A reverse split also became effective that day, and the ratio reported differed from one listing to another.
  • On November 2, 2026 the firm shared encouraging 12-month topline results from a Phase I/IIa Allocetra study, and on October 28, 2026 it announced that 135 participants had been randomized into a Phase 2b knee osteoarthritis study.

What Took Place

Enlivex Therapeutics (NASDAQ:ENLV) is a clinical-stage biotech based in Israel that develops cell-based immunotherapies. Its flagship product, Allocetra-OTS, is an off-the-shelf cell therapy built from apoptotic cells. Corporate announcements clustered in the last week of October and the first days of November 2026. A Nasdaq delisting notice and a stated plan to appeal were disclosed on October 27, 2026, with trial news arriving on October 28 and November 2, 2026. The screen registers a one-day decline of 20.79%, yet no single announcement has been confirmed as the trigger, so none is named here. Separately, the company noted that 135 patients were randomized in a Phase 2b study, a trial-design milestone rather than a readout of results.

How Reverse Splits and Notices Function

A reverse split combines shares into fewer, pricier units, which lifts the quoted price without altering what a holder owns. Firms pursue it to satisfy minimum bid requirements. When the stock slides again after such a split, the RSI, which compares average gains and losses across 14 sessions ranging from 0 to 100, can sink toward 11.69 even though the earlier price jump was purely mechanical. A delisting notice means shares could move to over-the-counter trading if an appeal does not succeed. The reasons behind this notice were not confirmed. Market data also shows a consensus target near USD 4,800, which appears to be a data error linked to the split. Since the price is so low, a few thousand shares traded can nudge the quote noticeably, which magnifies the RSI.

Risks and Monitoring Points

Given a market capitalisation near USD 2.19 million, a handful of trades may shift the price, bid-ask spreads could be broad and quoted moves may flip. Clinical-stage biotechs rely on trial results and funding, and the cash position of this company could not be located. Encouraging topline results from an early study do not demonstrate efficacy in a bigger Phase 2b trial. Track the Nasdaq appeal result, any fresh financing and the Phase 2b schedule. Reported split ratios conflicted, one-for-16 against one-for-15, so consult the company filings. Individual holders should also look into how many warrants or convertible securities exist, since those can add shares rapidly.

Where Things Stand

Enlivex screens as oversold because a delisting notice, a reverse split and sharp price swings landed at the same time, rather than from one confirmed trigger. The encouraging November 2, 2026 topline figures and the Phase 2b recruitment point to ongoing scientific progress, yet the share price is being pushed around by listing risk and a market capitalisation near USD 2.19 million. An RSI of 11.69 reflects selling pressure and offers no insight into the appeal. The next dated milestone is the Nasdaq appeal process, and no hearing date has been confirmed.